



CLAIMS

1. A cannabinoid receptor modulator containing a compound represented by Formula (I₀)



5 wherein, X is an oxygen atom, an optionally substituted sulfur atom or an optionally substituted imino group, R⁰ is an optionally substituted acylamino group, ring A⁰ is a benzene ring which may further have a substituent in addition to R⁰, and ring B is an optionally substituted 5-membered heterocycle, or a salt thereof or a prodrug thereof.


10 2. The modulator as described in Claim 1 wherein the compound represented by Formula (I₀) or a salt thereof or a prodrug thereof is a compound represented by Formula (I)



15

wherein, X is an oxygen atom, an optionally substituted sulfur atom or an optionally substituted imino group, R¹, R², R³ and R⁴ are independently a hydrogen atom, an optionally substituted hydrocarbon group, an optionally

substituted heterocyclic group, an optionally substituted hydroxyl group, an optionally substituted mercapto group or an optionally substituted amino group, or R² and R³ may be taken together to form a bond, or R¹ and R² may be taken
 5 with the adjacent carbon atom to form an optionally substituted ring, Y is -CO-, -SO-, or -SO₂-, R⁵ is a hydrogen atom or an optionally substituted hydrocarbon group, R⁶ is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted hydroxyl group or an optionally substituted amino group, or R⁵ and R⁶ may
 10 be taken with the adjacent carbon atom or sulfur atom and nitrogen atom to form an optionally substituted ring, and ring A is a benzene ring which may further have a substituent in addition to a group represented by the
 15 following formula



wherein, each symbol has the same meaning as described above, or a salt thereof or a prodrug thereof.

3. The modulator as described in Claim 2 wherein R¹ and R² are a hydrogen atom.
 20

4. The modulator as described in Claim 2 wherein R¹ and R² are respectively a hydrogen atom or a C₁₋₄ alkyl group, provided that R¹ and R² are not a hydrogen atom at the same

time.

5. The modulator as described in Claim 1 wherein the compound represented by Formula (I₀) or the salt thereof is a cannabinoid receptor agonist.

5 6. The modulator as described in Claim 5 wherein cannabinoid receptor is type 1 cannabinoid receptor.

7. The modulator as described in Claim 1 wherein the compound represented by Formula (I₀) or the salt thereof is a cannabinoid receptor antagonist.

10 8. The modulator as described in Claim 7 wherein the cannabinoid receptor is type 1 cannabinoid receptor.

9. The modulator as described in Claim 1 wherein the compound represented by Formula (I₀) or a salt thereof is type 2 cannabinoid receptor agonist.


15 10. The modulator as described in Claim 1 which is an agent of preventing, treating or pain-relieving acute cerebrovascular disorders, spinal damage, head injury, multiple sclerosis, glaucoma, depression, vomit, arthritis or asthma.

20 11. The modulator as described in Claim 1 which is an agent of preventing or treating memory disorders, psychiatric diseases, obesity, mental diseases, anxiety, depression, drug-dependency, Alzheimer's dementia or Parkinson's disease, or an aid for smoking cessation.

25 12. The modulator as described in Claim 1 which is an


agent of preventing or treating multiple sclerosis,
 neurodegenerative diseases, irritable bowel syndrome,
 Crohn's Disease, reflux oesophagitis, COPD, psoriasis,
 autoimmune diseases, graft rejection, allergic diseases,
 5 psychogenic pain, hepatitis virus or hypertension, or an
 agent of regulating immunity.

13. A compound represented by Formula (I')



wherein, X is an oxygen atom, an optionally substituted
 10 sulfur atom or an optionally substituted imino group, R¹
 and R² are independently a hydrogen atom, an optionally
 substituted hydrocarbon group, an optionally substituted
 heterocyclic group, an optionally substituted hydroxyl
 group, an optionally substituted mercapto group or an
 15 optionally substituted amino group, or R¹ and R² may be
 taken with the adjacent carbon atom to form an optionally
 substituted ring, R³' is a hydrogen atom, an optionally
 substituted hydrocarbon group, an optionally substituted
 hydroxyl group, an optionally substituted mercapto group or
 20 an optionally substituted amino group, R⁴' is a hydrogen
 atom, an optionally substituted alkyl group, an optionally
 substituted aryl group, or an optionally substituted

heterocyclic group, Y is -CO-, -SO-, or -SO₂-, R⁵ is a hydrogen atom or an optionally substituted hydrocarbon group, R^{6'} is an optionally substituted hydrocarbon group (provided that both of R¹ and R² are not a hydrogen atom, R^{6'} has no benzene ring), an optionally substituted hydroxyl group or an optionally substituted amino group, and ring A' is a benzene ring which may have further substituent in addition to a group represented by the following formula



10

wherein, each symbol has the same meaning as described above, or a salt thereof.

14. The compound as described in Claim 13 wherein R¹ and R² are independently a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, an optionally substituted hydroxyl group, an optionally substituted mercapto group or an optionally substituted amino group.

15. The compound as described in Claim 13 wherein R¹ and R² are a hydrogen atom.

16. The compound as described in Claim 13 wherein R¹ and R² are respectively a hydrogen atom or a C₁₋₄ alkyl group, provided that R¹ and R² are not a hydrogen atom at the same

time.

17. The compound as described in Claim 13 wherein R^{3'} is a hydrogen atom.

18. The compound as described in Claim 13 wherein R^{4'} is 5 an optionally substituted C₆₋₁₄ aryl group or an optionally substituted 5 to 14-membered heterocyclic group.

19. The compound as described in Claim 13 wherein R^{4'} is an optionally substituted phenyl group.


20. The compound as described in Claim 19 wherein R^{4'} is a 10 phenyl group which may be substituted with an optionally substituted C₁₋₄ alkyl group or an optionally substituted C₁₋₄ alkoxy group.

21. The compound as described in Claim 13 wherein Y is - CO-.

15 22. The compound as described in Claim 13 wherein R⁵ is a hydrogen atom.

23. The compound as described in Claim 13 wherein X is an oxygen atom.

24. The compound as described in Claim 13 wherein 5- 20 position of the fused-heterocycle in Formula (I') is substituted by a group represented by the following formula




wherein, each symbol has the same meaning as described

above.

25. The compound as described in Claim 24 wherein 7-position of the fused-heterocycle in Formula (I') is further substituted by an optionally substituted C₆₋₁₄ aryl-C₁₋₄ alkyl group.

26. The compound as described in Claim 25 wherein the optionally substituted C₆₋₁₄ aryl-C₁₋₄ alkyl group is an optionally substituted benzyl group.

27. The compound as described in Claim 13 wherein ring A' is a benzene ring which may further have 1 to 3 substituents selected from an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₆₋₁₂ aryl group, an optionally substituted 5- or 6-membered heterocyclic group and an acyl group in addition to a group represented by the following formula



wherein, each symbol has the same meaning as described above.

28. The compound as described in Claim 27 wherein 7-position of the fused-heterocycle in Formula (I₀) is substituted by an optionally substituted C₁₋₄ alkyl group, an optionally substituted C₆₋₁₂ aryl group, an optionally substituted 5- or 6-membered heterocyclic group, or an acyl

group.

29. The compound as described in Claim 27 wherein 7-position of the fused-heterocycle in Formula (I₀) is substituted by an phenyl group, a furanyl group, a thiienyl group, a pyridyl group, an acetyl group, a propionyl group, a butyryl group, or a benzoyl group, which may be substituted, respectively.

30. N-(3-(4-isopropylphenyl)-4,6,7-trimethyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide,
10 (+)-N-((3R)-3-(4-isopropylphenyl)-4,6,7-trimethyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide,
 N-(7-acetyl-3-(4-isopropylphenyl)-4,6-dimethyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide,
 N-(3-(4-isopropylphenyl)-7-methoxy-4,6-dimethyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide,
15 (+)-N-((3R)-7-acetyl-3-(4-isopropylphenyl)-4,6-dimethyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide,
 (+)-N-(tert-butyl)-N'-((3R)-3-(4-isopropylphenyl)-4,6,7-trimethyl-2,3-dihydro-1-benzofuran-5-yl)urea,
20 N-(3-(4-isopropylphenyl)-4,6-dimethyl-7-phenyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide,
 N-(7-(3-dimethylaminophenyl)-3-(4-isopropylphenyl)-4,6-dimethyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide,
25

N-(3-hydroxypropyl)-N'-(3-(4-isopropylphenyl)-4,6,7-trimethyl-2,3-dihydro-1-benzofuran-5-yl)urea,
 N-((4-isopropyl-3-(2-methoxyethoxy)-4-isopropylphenyl)-4,6,7-trimethyl-2,3-dihydro-1-benzofuran-5-yl))-3,3-dimethylbutanamide,

N-(7-(4-isopropylbenzyl)-3,4,6-trimethyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide,


N-(3-(4-tert-butylphenyl)-2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide, or

10 N-(3-(4-isopropylphenyl)-4,6,7-trimethyl-3H-spiro(1-benzofuran-2,1'-cyclopentan)-5-yl)-3,3-dimethylbutanamide.

31. A prodrug of the compound as described in Claim 13.

32. A drug comprising the compound as described in Claim 13 or a prodrug thereof.

15 33. A method of preventing treating or pain-relieving acute cerebrovascular disorders, spinal damage, head injury, multiple sclerosis, glaucoma, depression, vomit, arthritis or asthma, which is characterized by administering an effective amount of a compound represented by Formula (I₀)




20

wherein, X is an oxygen atom, an optionally substituted sulfur atom or an optionally substituted imino group, R° is an acylamino group, ring A° is a benzene ring which may

further have a substituent in addition to R^0 , and ring B is an optionally substituted 5-membered heterocycle, or a salt thereof or a prodrug thereof to a subject in need of such treatment.


5 34. A method of preventing or treating memory disorders, psychiatric diseases, obesity, mental diseases, anxiety, depression, drug-dependency, Alzheimer's dementia or Parkinson's disease, or a method of aiding smoking cessation, which is characterized by administering an
10 effective amount of a compound represented by Formula (I₀)



wherein, X is an oxygen atom, an optionally substituted sulfur atom or an optionally substituted imino group, R° is an acylamino group, ring A° is a benzene ring which may
15 further have a substituent in addition to R°, and ring B is an optionally substituted 5-membered heterocycle, or a salt thereof or a prodrug thereof to a subject in need of such treatment.


35. A method of preventing or treating multiple sclerosis,
20 neurodegenerative diseases, irritable bowel syndrome, Crohn's Disease, reflux oesophagitis, COPD, psoriasis, autoimmune diseases, graft rejection, allergic diseases, psychogenic pain, hepatitis virus or hypertension, or a

method of regulating immunity, which is characterized by administering an effective amount of a compound represented by Formula (I₀)



5 wherein, X is an oxygen atom, an optionally substituted sulfur atom or an optionally substituted imino group, R⁰ is an acylamino group, ring A⁰ is a benzene ring which may further have a substituent in addition to R⁰, and ring B is an optionally substituted 5-membered heterocycle, or a salt
10 thereof or a prodrug thereof to a subject in need of such treatment.


36. Use of a compound represented by Formula (I₀)



wherein, X is an oxygen atom, an optionally substituted sulfur atom or an optionally substituted imino group, R⁰ is an acylamino group, ring A⁰ is a benzene ring which may further have a substituent in addition to R⁰, and ring B is an optionally substituted 5-membered heterocycle, or a salt
15 thereof or a prodrug thereof, for manufacturing an agent of
20 preventing or treating acute cerebrovascular disorders, spinal damage, head injury, multiple sclerosis, glaucoma,


depression, vomit, arthritis or asthma; or for manufacturing an analgesic agent.

37. Use of a compound represented by Formula (I₀)



5 wherein, X is an oxygen atom, an optionally substituted sulfur atom or an optionally substituted imino group, R° is an acylamino group, ring A° is a benzene ring which may further have a substituent in addition to R°, and ring B is an optionally substituted 5-membered heterocycle, or a salt thereof or a prodrug thereof, for manufacturing an agent of preventing or treating memory disorders, psychiatric diseases, obesity, mental diseases, anxiety, depression, drug-dependency, Alzheimer's dementia or Parkinson's disease, or an aid for smoking cessation.


10 15 38. Use of a compound represented by Formula (I₀)



wherein, X is an oxygen atom, an optionally substituted sulfur atom or an optionally substituted imino group, R° is an acylamino group, ring A° is a benzene ring which may further have a substituent in addition to R°, and ring B is an optionally substituted 5-membered heterocycle, or a salt


thereof or a prodrug thereof, for manufacturing an agent of preventing or treating multiple sclerosis, neurodegenerative diseases, irritable bowel syndrome, Crohn's Disease, reflux oesophagitis, COPD, psoriasis, 5 autoimmune diseases, graft rejection, allergic diseases, psychogenic pain, hepatitis virus or hypertension, or an agent of regulating immunity.

39. A method of preparing a compound represented by the following formula



10

wherein, each symbol has the same meaning as described below, or a salt thereof, comprising reacting a compound represented by the following formula



15

wherein, X is an oxygen atom, an optionally substituted sulfur atom or an optionally substituted imino group, R¹, R², R³ and R⁴ are independently a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, an optionally substituted

hydroxyl group, an optionally substituted mercapto group or an optionally substituted amino group, or R² and R³ may be taken together to form a bond, or R¹ and R² may be taken with the adjacent carbon atom to form an optionally
5 substituted ring,

R⁵ is a hydrogen atom or an optionally substituted hydrocarbon group, R⁶ is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted hydroxyl group or an optionally substituted amino group, or
10 R⁵ and R⁶ may be taken with the adjacent carbon atom or sulfur atom and nitrogen atom to form an optionally substituted ring, and

ring A is a benzene ring which may have further substituent in addition to a group represented by Formula -NHR₅
15 (wherein, each symbol has the same meaning as described above), or a salt thereof with,

R⁶YL, (R⁶Y)₂O or R⁶N=Y, wherein, L is a leaving group, and Y is -CO-, -SO-, or -SO₂-.